Abstract. Uric acid (UA) is the final oxidation product of purine metabolism. Hyperuricemia has been previously reported to contribute to vascular endothelial dysfunction and the development of cardiovascular diseases, metabolic syndrome and chronic kidney diseases. In addition, it has been reported that fibroblast growth factor 21 (FGF21) can exert regulatory effects on UA-induced lipid accumulation. Therefore, the present study aimed to investigate the possible role of FGF21 in HUVEC cell injury induced by UA. The study used UA to induce HUVEC cell injury, inhibited sirtuin 1 (Sirt1) expression using EX527 and overexpressed FGF21 by transfection. Subsequently, reverse transcription-quantitative PCR was performed to measure the mRNA expression levels of FGF21, Sirt1 and inflammatory cytokines TNF-α, IL-1β and IL-6, whereas western blotting was performed to measure their corresponding protein expression levels including FGF21, Sirt1, NLR family pyrin domain containing 3, pro-caspase1, apoptosis-associated speck-like protein containing a CARD, activating transcription factor 4, C/EBP homologous protein and eukaryotic initiation factor 2. Furthermore, dichloro-dihydro-fluorescein diacetate staining was performed to measure intracellular reactive oxygen species (ROS) generation in HUVECs. The levels of ROS and nitric oxide were also quantified using commercial assay kits. The results demonstrated that overexpression of FGF21 significantly inhibited UA treatment-induced endoplasmic reticulum (ER) stress, inflammation and oxidative stress in HUVECs. Furthermore, overexpression of FGF21 significantly activated Sirt1. The sirt1 inhibitor, EX527, significantly abrogated the suppressive effects of FGF21 overexpression on ER stress, inflammation and oxidative stress in UA-stimulated HUVECs. To conclude, results of the present study suggested that FGF21 may attenuate UA-induced ER stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1. Therefore, FGF21 may be a potential effective target for the future treatment of vascular endothelial cell dysfunction.

Introduction

Uric acid (UA) is the final oxidation product of purine metabolism (1). It has been reported that high levels of UA in the serum are closely associated with the development of gout and kidney stones (2). UA crystallization triggers robust inflammation and immune activation, which serves an important role in the development of numerous diseases, including hypertension, atherosclerosis and diabetes (3,4). Increasing epidemiological evidence suggests that hyperuricemia is an independent risk factor for the development of cardiovascular diseases, metabolic syndrome and chronic kidney diseases (5,6). Furthermore, hyperuricemia contributes to vascular endothelial dysfunction and the development of hypertension (7). High serum UA levels have been observed in hypertensive adolescents, where UA reduction can be used to treat hypertension (8). Therefore, it is important to determine the role of UA in vascular endothelial cells.

FGF21 is a hormone-like member of the FGF family that can regulate energy homeostasis, systemic glucose and lipid metabolism (9,10). FGF21 has been reported to alleviate HUVEC apoptosis by inhibiting the Fas signaling pathway, which ameliorates atherosclerosis in apoE-/-mice (11). Furthermore, FGF21 has been found to alleviate oxidized low-density lipoprotein (ox-LDL)-induced HUVEC pyroptosis through the tet methylcytosine dioxygenase (TET2)/ubiquinol cytochrome c reductase core protein I (UQCRCI)/reactive oxygen species (ROS) signaling pathway (12). Another previous study also demonstrated FGF21 to protect HUVECs against high glucose-induced oxidative stress and apoptosis by activating the PI3K/AKT/FOXO3a signaling pathway (13). However, the role of FGF21 in vascular endothelial cell injury induced by UA remains unclear. It has previously been reported that FGF21 knockdown can reverse the inhibitory effects of the microRNA-149-5p inhibitor on the PI3K/AKT/FOXO3a signaling pathway (14). Therefore, FGF21 may be a potential effective target for the future treatment of vascular endothelial cell dysfunction.
lipid accumulation induced by high UA levels (14). Therefore, the present study aimed to investigate the role of FGF21 in vascular endothelial cell injury induced by UA.

In the present study, HUVECs were induced using different concentrations of UA to establish a vascular endothelial cell injury model in vitro, which was then applied to investigate the role of FGF21 in vascular endothelial cell injury induced by UA.

Materials and methods

Cell culture and treatment. The human umbilical vein endothelial HUVEC-C cell line (CRL-1730) was purchased from the American Type Culture Collection and maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO². HUVECs were stimulated with 6, 9 and 12 mg/dl concentrations of UA (cat. no. U2625; Sigma-Aldrich; Merck KGaA) for 24 h at room temperature. Sirtuin 1 (sirt1) expression was inhibited by EX527 (10 µM; Beyotime Institute of Biotechnology) (15). Untreated cells were used as the control group.

Cell transfection. For transfection, the FGF21 overexpression plasmid (Ov-FGF21; 10 nM) and the control empty vector (Ov-NC; 10 nM) were purchased from Shanghai GenePharma Co., Ltd. Subsequently, Ov-FGF21 or Ov-NC, were transfected into cells (2x10⁶ cells/well) for 48 h at 37°C using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. HUVECs were used for subsequent experimentation 48 h post-transfection and reverse transcription (RT)-quantitative (q)PCR analysis was performed to confirm transfection efficiency. In addition, cells were co-treated with EX527. After transfection for 48 h, cells were then exposed to UA for 24 h.

RT-qPCR. Total RNA was extracted from HUVECs using TRIzol® (Thermo Fisher Scientific, Inc.) following the manufacturer’s instructions. RT was performed using the PrimeScript RT reagent kit (Takara Bio, Inc.) according to the manufacturer’s instructions. RT was performed using the PrimeScript RT-reagent kit (Takara Bio, Inc.) following the manufacturer’s instructions. For RT the following temperature protocol was used; 15 min at 42°C; followed by 5 min at 98°C. The reaction volume was 20 µl. qPCR was performed using the SYBR® Green Quantitative RT-qPCR Kit (cat. no. QR0100; Sigma-Aldrich; Merck KGaA). The following thermocycling conditions were used for the qPCR: Initial denaturation at 95°C for 30 sec; followed by 40 cycles at 95°C for 5 sec and 60°C for 30 sec. The reaction volume was 20 µl. The mRNA expression levels of FGF21, sirt1, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) were quantified using the 2−ΔΔCq method (16) and normalized to the internal reference gene, GAPDH. Primer sequences were synthesized by Shanghai GenePharma Co., Ltd. and are displayed in Table I.

Western blotting. Total protein was extracted from HUVECs using the RIPA lysis buffer (cat. no. P0013C; Beyotime Institute of Biotechnology) and protein concentration was determined using a BCA Protein Assay Kit (cat. no. P0012A; Beyotime Institute of Biotechnology). Total protein (30 µg/lane) was separated via SDS-PAGE on a 10% gel (Beyotime Institute of Biotechnology) and transferred onto PVDF membranes (EMD Millipore). The membranes were blocked with 5% skimmed milk for 2 h at room temperature, followed by overnight incubation at 4°C with primary antibodies. Following incubation with the primary antibody and washing with TBST (0.1% Tween-20; 10 min at room temperature), the membranes were incubated with a goat HRP-conjugated anti-rabbit secondary antibody (1:5,000; cat. no. S0001; Affinity Biosciences) for 2 h at room temperature. Protein bands were visualized using an ECL Kit (Beyotime Institute of Biotechnology). Protein expression levels were semi-quantified using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc.; Roper Technologies, Inc.). The primary antibodies used were as follows: FGF21 (1:1,000; cat. no. ab64857; Abcam), sirt1 (1:2,000; cat. no. ab12193; Abcam), activating transcription factor 4 (ATF4; 1:500; cat. no. ab2j6839; Abcam), NLR family pyrin domain containing 3 (NLRP3; 1:500; cat. no. ab2j485; Abcam), pro-caspase 1 (1:1,000; cat. no. ab179515; Abcam), apoptosis-associated speck-like protein containing a CARD (ASC; 1:1,000; cat. no. ab70627; Abcam), phosphorylated (p)-AKT (1:1,000; cat. no. ab38449; Abcam), AKT (1:1,000; cat. no. ab8805; Abcam), p-endothelial nitric oxide synthase (p-eNOS; 1:500; cat. no. ab184154; Abcam), eNOS (1:1,000; cat. no. ab5589; Abcam), GAPDH (1:2,500; cat. no. ab9485; Abcam), C/EBP homologous protein (CHOP; 1:1,000; cat. no. DF6025; Affinity Biosciences), p-eukaryotic initiation factor 2 (p-eIF2A; 1:500; cat. no. AF6087; Affinity Biosciences), p-endothelial nitric oxide synthase (p-eNOS; 1:500; cat. no. AF6087; Affinity Biosciences), C/EBP homologous protein (CHOP; 1:1,000; cat. no. AF6087; Affinity Biosciences), C/EBP homologous protein (CHOP; 1:1,000; cat. no. AF6087; Affinity Biosciences).

Assessment of ROS and nitric oxide (NO) levels. Intracellular ROS generation was quantified as previously described (17). HUVECs were inoculated in six-well plates (5x10⁵ cells/well) and incubated with 10 µM dichloro-dihydro-fluorescein diacetate (DCFH-DA; Sigma-Aldrich; Merck KGaA) at 37°C using a BCA Protein Assay Kit (cat. no. P0012A; Beyotime Institute of Biotechnology). Total protein (30 µg/lane) was separated via SDS-PAGE on a 10% gel (Beyotime Institute of Biotechnology) and transferred onto PVDF membranes (EMD Millipore). The membranes were blocked with 5% skimmed milk for 2 h at room temperature, followed by overnight incubation at 4°C with primary antibodies. Following incubation with the primary antibody and washing with TBST (0.1% Tween-20; 10 min at room temperature), the membranes were incubated with a goat HRP-conjugated anti-rabbit secondary antibody (1:5,000; cat. no. S0001; Affinity Biosciences) for 2 h at room temperature. Protein bands were visualized using an ECL Kit (Beyotime Institute of Biotechnology). Protein expression levels were semi-quantified using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc.; Roper Technologies, Inc.). The primary antibodies used were as follows: FGF21 (1:1,000; cat. no. ab64857; Abcam), sirt1 (1:2,000; cat. no. ab12193; Abcam), activating transcription factor 4 (ATF4; 1:500; cat. no. ab2j6839; Abcam), NLR family pyrin domain containing 3 (NLRP3; 1:500; cat. no. ab2j485; Abcam), pro-caspase 1 (1:1,000; cat. no. ab179515; Abcam), apoptosis-associated speck-like protein containing a CARD (ASC; 1:1,000; cat. no. ab70627; Abcam), phosphorylated (p)-AKT (1:1,000; cat. no. ab38449; Abcam), AKT (1:1,000; cat. no. ab8805; Abcam), p-endothelial nitric oxide synthase (p-eNOS; 1:500; cat. no. ab184154; Abcam), eNOS (1:1,000; cat. no. ab5589; Abcam), GAPDH (1:2,500; cat. no. ab9485; Abcam), C/EBP homologous protein (CHOP; 1:1,000; cat. no. DF6025; Affinity Biosciences), p-eukaryotic initiation factor 2 (p-eIF2A; 1:500; cat. no. AF6087; Affinity Biosciences).

Table I. Sequences of primers used for reverse transcription-quantitative PCR.

| Gene      | Sequence (5′→3′) |
|-----------|------------------|
| FGF21     | F: CTGTGGGTTTCTGTGGCGTGG R: CCGGCTTCAAGGGTTTTCAG |
| SIRT1     | F: AAGTTGACTGTAAGCTGTCAG R: TGCTACTGGTTTTACCCAGGG |
| TNF-α     | F: TCTCGAACCCTCGAGTACAAA R: TATCTCTCGACATTACACCCCA |
| IL-1β     | F: GCCCTTAAACAGATGAAGTG R: GTAGTGTTGTCCGAGATTC |
| IL-6      | F: CCTCTCCTCAACCGGCCTTC R: GGCAAGTGCTTCCTCATTGATC |
| GAPDH     | F: GGAAGCGGATCCCCCTCAAAT R: GGCTGTGTCATACCTTCATGG |

FGF21, fibroblast growth factor 21; SIRT1, sirtuin 1; F, forward; R, reverse.

Using Intracellular ROS and Nitric Oxide (NO) Levels to Assess the Role of FGF21 in Vascular Endothelial Cell Injury
for 30 min in the dark. In the presence of ROS, DCFH-DA is oxidized and produces fluorescence (18). Cells were washed three times with pre-cooled PBS and ROS levels were determined using a fluorescence microscope (magnification, x200), with excitation and emission wavelengths of 485 and 520 nm, respectively. ROS levels were also quantified using a Fluorometric Intracellular ROS Kit (cat. no. MAK143; Sigma-Aldrich; Merck KGaA), according to the manufacturer's protocols.

NO levels were quantified using a NO Assay Kit (cat. no. A012-1-2; Nanjing Jiancheng Bioengineering Institute). According to the manufacturer's protocols, the mixed reagents were added sequentially to the samples. After standing at room temperature for 40 min, the samples were centrifuged at 1,000 x g at 4˚C for 10 min. The supernatant was removed and color developer was added. After 10 min at room temperature, the absorbance was detected at 550 nm using a microplate reader (Bio-Rad Laboratories, Inc.).

Statistical analysis. Statistical analysis was performed using GraphPad Prism 8.0 software (GraphPad Software, Inc.). Data are presented as the mean ± standard deviation of ≥ three independent experiments. One-way ANOVA was used to compare differences between three or more groups followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results

High UA inhibits FGF21 and Sirt1 expression levels and promotes endoplasmic reticulum (ER) stress in HUVECs. The mRNA and protein expression levels of FGF21 and sirt1 in UA-stimulated HUVECs were determined via RT-qPCR and western blotting, respectively. As presented in Fig. 1A and B, the mRNA and protein expression levels of FGF21 and sirt1 were significantly decreased following UA stimulation in a dose-dependent manner compared with those in the 0 mg/dl UA group (control group). Furthermore, the protein expression levels of ER stress-associated proteins ATF4, CHOP, p-eIF2A and eIF2A were also quantified using western blotting. As shown in Fig. 1C, the protein expression levels of ATF4, CHOP, and eIF2A phosphorylation were all significantly increased in UA-stimulated HUVECs, in a dose-dependent manner compared with those in the 0 mg/dl UA group. Furthermore, when the concentration of UA was 12 mg/dl, the highest difference was observed compared with that in the 0 mg/dl UA group. Therefore, 12 mg/dl UA was selected for subsequent experimentation. These results suggest that the expression levels of FGF21 and sirt1 may be closely associated with the progression of UA-induced vascular endothelial cell injury.

Overexpression of FGF21 activates sirt1 and suppresses ER stress in HUVECs. FGF21 was overexpressed via transfection of HUVEC with the Ov-FGF21 plasmid. RT-qPCR analysis demonstrated that the Ov-FGF21 plasmid was successfully transfected into HUVECs, since the Ov-FGF21 plasmid transfection significantly increased FGF21 expression compared with that in UA-induced HUVECs (Fig. 2A). FGF21 was significantly upregulated in the UA + Ov-FGF21 group compared with that in the UA + Ov-NC group, indicating that the Ov-FGF21 plasmid was also successfully transfected into UA-induced HUVECs (Fig. 2B and C). Subsequently, Sirt1 mRNA and protein expression levels in the transfected cells were measured (Fig. 2D and E). Compared with those
in the UA + Ov-NC group, overexpression of FGF21 was demonstrated to significantly increase sirt1 mRNA and protein expression levels. The protein expression levels of ATF4, CHOP and eIF2A phosphorylation were significantly decreased in the UA + Ov-FGF21 group compared with those in the UA + Ov-NC group (Fig. 2F). Collectively, these results suggest that FGF21 may activate sirt1 and inhibit ER stress.

Overexpression of FGF21 attenuates ER stress and the inflammatory response in high UA-induced HUVECs by activating sirt1. EX527 was used as a sirt1 inhibitor for subsequent experiments. As presented in Fig. 3, the protein expression levels of ATF4, CHOP and eIF2A phosphorylation in HUVECs were significantly higher in the UA + Ov-FGF21 + EX527 group compared with those in the UA + Ov-FGF21 group (Fig. 2F). Collectively, these results suggest that FGF21 may activate sirt1 and inhibit ER stress.

Figure 3. Overexpression of FGF21 attenuates endoplasmic reticulum stress in high UA-induced HUVECs by activating Sirtuin 1. Western blotting was performed to detect the protein levels of ATF4, CHOP, p-eIF2A and eIF2A. ***P<0.001 vs. control. ###P<0.001 vs. UA + Ov-NC; $$$P<0.001 vs. UA + Ov-FGF21. FGF21, fibroblast growth factor 21; UA, uric acid; ATF4, activating transcription factor 4; eIF2A, eukaryotic initiation factor 2; Ov, overexpressed; p-, phosphorylated; NC, negative control.

The mRNA expression levels of TNFα, IL-1β and IL-6 were next detected by RT-qPCR analysis. As presented in Fig. 4A, UA stimulation significantly promoted the expression of inflammatory cytokines TNFα, IL-1β and IL-6, compared with that in the control group. Following FGF21 overexpression, the mRNA expression levels of these inflammatory cytokines were significantly suppressed compared with those in the UA + Ov-NC group. However, after EX527 was added, this suppression of inflammatory cytokine mRNA expression levels by FGF21 was significantly reversed compared with that in the UA + Ov-FGF21 group. The protein expression levels of NLRP3, pro-caspase 1 and ASC, which are inflammatory proteins, were measured using western blotting (19). As presented in Fig. 4B, the protein expression levels of NLRP3, pro-caspase 1 and ASC were significantly increased following UA stimulation compared with those in the control group. By contrast, compared with those in the UA + Ov-NC group their
protein expression levels were significantly inhibited following the overexpression of FGF21. Furthermore, EX527 significantly reversed the inhibitory effects of FGF21 on the protein expression levels of NLRP3, pro-caspase 1 and ASC compared with those in the UA + Ov-NC group. These results suggest that the overexpression of FGF21 may attenuate ER stress and inflammatory injury in high UA-induced HUVECs by activating Sirt1.

Overexpression of FGF21 attenuates oxidative stress and vascular endothelial cell dysfunction in high UA-induced HUVECs by activating Sirt1. The levels of ROS and NO in HUVECs were measured. Results from DCFH-DA staining and commercial assay kits demonstrated that UA stimulation significantly promoted ROS generation compared with that in the control group. Furthermore, overexpression of FGF21 significantly inhibited ROS generation in UA-stimulated HUVECs compared with that in the UA + Ov-NC group, whereas the sirt1 inhibitor EX527 significantly reversed this effect compared with that in the UA + Ov-FGF21 group (Fig. 5A and B). Collectively, these results suggest that FGF21 can potentially inhibit ROS production by activating Sirt1.

As shown in Fig. 6A, NO levels were significantly decreased following UA stimulation compared with those in the control group. However, NO levels were significantly increased following the overexpression of FGF21 compared with those in the UA + Ov-NC group. Furthermore, treatment with the Sirt1 inhibitor EX527 significantly attenuated NO levels following the overexpression of FGF21 compared with those in the UA + Ov-FGF21 group. In addition, UA stimulation significantly decreased the
Figure 5. Overexpression of FGF21 attenuates oxidative stress in high UA-induced HUVECs by activating sirtuin 1. (A) ROS production was assessed via dichloro-dihydro-fluorescein diacetate staining (magnification, x200). (B) ROS levels were quantified using a ROS assay kit. ***P<0.001 vs. control; ###P<0.001 vs. UA + Ov-NC; $$$$P<0.001 vs. UA + Ov-FGF21. FGF21, fibroblast growth factor 21; UA, uric acid; ROS, reactive oxygen species; Ov, overexpressed; NC, negative control.

Figure 6. Overexpression of FGF21 attenuates vascular endothelial cell dysfunction in high UA-induced HUVECs by activating Sirtuin 1. (A) NO levels were quantified using a NO assay kit. (B) Western blotting was performed to detect the protein levels of p-AKT, AKT, p-eNOS and eNOS. (C) Semi-quantification of p-AKT/AKT and p-eNOS/eNOS ratios. ***P<0.001 vs. control; $$$$P<0.001 vs. UA + Ov-NC; $P<0.05, $$$P<0.01 and $$$$P<0.001 vs. UA + Ov-FGF21. FGF21, fibroblast growth factor 21; UA, uric acid; NO, nitric oxide; eNOS, endothelial NO synthase; Ov, overexpressed; NC, negative control; p-, phosphorylated.
Discussion

Hyperuricemia occurs when UA levels are elevated in the blood, increasing the risk of gout and nephrolithiasis (20). Hyperuricemia is considered a risk factor for a number of disorders, including diabetes mellitus, cardiovascular diseases and metabolic syndrome (21). Accumulating evidence suggests that UA can cause endothelial injury and dysfunction, though the mechanism remain unclear (22,23). Apoptosis induced by ox-LDL in vascular endothelial cells is an important process in the progression of atherosclerosis (11). FGF21 has been reported to be closely associated with metabolic dysfunction, including the development of vascular calcification and atherosclerotic disease (24-26). In the present study, UA stimulation was found to significantly decrease FGF21 mRNA and protein expression, suggesting a potential association between FGF21 and UA-induced vascular endothelial cell injury. Therefore, the present study aimed to investigate the role of FGF21 in a vascular endothelial cell injury model induced by UA.

Activation of ER stress, which frequently occurs using diabetes and metabolic syndrome, can cause endothelial dysfunction (27). The eIF2A/ATF4/CHOP signaling pathway serves an important role in regulating ER stress (28). The results of the present study demonstrated that UA stimulation significantly activated ER stress. Notably, overexpression of FGF21 suppressed the activation of ER stress in UA-stimulated HUVECs, which suggested that FGF21 may exert protective effects on HUVECs against ER stress. To investigate the detailed mechanism underlying the role of FGF21 in UA-stimulated cells, a series of in vitro experiments were performed.

A previous study reported that FGF21 can protect against angiotensin II-induced cardiac hypertrophy and dysfunction in a Sirt1-dependent manner (29). Furthermore, FGF21 has been found to promote the formation of aerobic myob fibers through the Sirt1-mediated signaling pathway (30). Results of the present study demonstrated that Sirt1 mRNA and protein expression were significantly decreased following UA stimulation. However, overexpression of FGF21 significantly increased Sirt1 expression. Therefore, the Sirt1 inhibitor, EX527, was used to determine whether Sirt1 was a downstream molecule of FGF21. The results of the present study demonstrated that EX527 significantly reversed the suppressive effects of FGF21 overexpression on ER stress in UA-stimulated HUVECs. ER stress can activate the NLRP3 inflammasome to induce inflammatory responses and oxidative stress (31). However, FGF21 can ameliorate atherosclerosis by inhibiting NLRP3 inflammasome-related cell pyroptosis and ER stress in vascular endothelial cells (32). In the present study, overexpression of FGF21 significantly decreased the expression levels of inflammatory cytokines and components of the NLRP3 inflammasome, which were partially reversed by the Sirt1 inhibitor. Taken together, these results suggested that FGF21 may exert a suppressive effect on ER stress and inflammation by activating Sirt1.

Generation of ROS, reduction in eNOS activity and therefore decreased NO release are considered to be a prominent mechanism underlying endothelial injury (22). It has been previously reported that NO production is reduced in a the high UA-induced hyperuricemia model (22), which is consistent with the results of the present study. The results demonstrated that UA stimulation induced oxidative stress and vascular endothelial cell dysfunction, as demonstrated by the significantly increased ROS production, significant decline in NO release and the significant decrease in eNOS activity in UA-stimulated HUVECs in the present study. However, these effects were significantly reversed following overexpression of FGF21. EX527 significantly abrogated the suppressive effects of FGF21 overexpression on oxidative stress and vascular endothelial cell dysfunction. These results suggest that FGF21 may attenuate UA-induced ER stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1.

In conclusion, results of the present study suggest that FGF21 can attenuate ER stress, inflammatory injury and endothelial cell dysfunction caused by high UA by Sirt1 activation. However, the experimental sirt1 inhibitor, EX527, only partially reversed the effects of FGF21, suggesting that FGF21 may also act through other signaling pathways, which warrants further exploratory studies.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Scientific Research Fund of Sichuan Health and Health Committee (grant no. 19PJ114).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

RO, XZ, RZ and DD conceived and designed the study. RO, XZ, RZ, JY and SL collected and analyzed the data. All authors were involved in the writing of the manuscript and revised the manuscript. RO and DD confirm the authenticity of all the raw data. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.
Hyperuricemia, acute and chronic

**References**

1. Yang X, Gu J, Lv H, Li H, Cheng Y, Liu Y and Jiang Y: Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)relin receptor. Biomed Pharmacother 109: 1163‑1170, 2019.

2. Ramirez-Sandoval JC and Madero M: Treatment of hyperuricemia in chronic kidney disease. Contrib Nephrol 192: 135‑146, 2018.

3. Ng G, Chau EM and Shi Y: Recent developments in immune activation by uric acid crystals. Arch Immunol Ther Exp (Warsz) 58: 273‑277, 2010.

4. Stodle GS, Silva GB, Tangeras LH, Gierman LM, Nervik I, Dahlberg UE, Sun C, Aune MH, Thomsen LCV, Bjørge L and Iversen AC: Placental inflammation in pre‑eclampsia by Nod‑like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clin Exp Immunol 193: 84‑94, 2018.

5. Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, Zhang F, Zheng W and Zhang D: Hyperuricemia and cardiovascular disease. Curr Pharm Des 25: 700‑709, 2019.

6. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lorada LG, et al: Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis 71: 851‑865, 2018.

7. Choi YJ, Yoon Y, Lee KY, Hien TT, Kim KC, Lee J, Lee MY, Lee SM, Kang DH and Lee BH: Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J 28: 3197‑3204, 2014.

8. Assafi F: Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. J Nephrol 27: 51‑56, 2014.

9. Alonge KM, Meares GP and Hillgartner FB: Glucagon and insulin cooperatively stimulate fibroblast growth factor 21 gene transcription by increasing the expression of activating transcription factor 4. J Biol Chem 292: 5239‑5252, 2017.

10. Brahma MK, Adam RC, Pollak NM, Jaeger D, Zierler KA, Alonge KM, Meares GP and Hillgartner FB: Glucagon and insulin cooperatively stimulate fibroblast growth factor 21 gene transcription by increasing the expression of activating transcription factor 4. J Biol Chem 292: 5239‑5252, 2017.

11. Guo D, Xiao L, Hu H, Liu M, Yang L and Lin X: FGF21 protects human umbilical vein endothelial cells against high glucose‑induced apoptosis via PI3K/Akt/Fox3a signaling pathway. J Diabetes Complications 32: 729‑736, 2018.

12. Chen S, Chen D, Yang H, Wang X, Wang J and Xu C: Uric acid induced hepatocytes lipid accumulation through regulation of miR‑149‑3p/FGF21 axis. BMC Gastroenterol 20: 39, 2020.

13. Liu ZH, Zhang Y, Wang X, Fan XF, Zhang Y, Li X, Gong YS and Han LP: SIRT1 activation attenuates cardiac fibrosis by endothelial‑to‑mesenchymal transition. Biomed Pharmacother 118: 109227, 2019.

14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real‑time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.

15. Wu X, Pan C, Chen R, Zhang S, Zhai Y and Guo H: BML‑111 attenuates high glucose‑induced inflammation, oxidative stress and reduces extracellular matrix accumulation via targeting Nrf2 in rat glomerular mesangial cells. Int Immunopharmacol 79: 106108, 2020.

16. Aranda A, Sequeido L, Tolosa L, Quintas G, Burello E, Castell JV and Gombau L: Dichloro‑dihydro‑fluorescein diacetate (DCFH‑DA) assay: A quantitative method for oxidative stress assessment of nanoparticle‑treated cells. Toxicol In Vitro 27: 595‑603, 2013.

17. Liu HD, Li W, Chen ZR, Hu YC, Zhang DD, Shen W, Zhou ML, Zhu L and Hang CH: Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem Res 38: 2072‑2083, 2013.

18. Li Z, Zhang Y and Zeng C: Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 12: 3167‑3181, 2020.

19. George C and Minter DA: Hyperuricemia. In: StatPearls (Internet). StatPearls Publishing, Treasure Island, FL, 2021.

20. Hong Q, Wang L, Huang Z, Feng Z, Cui S, Fu B, Cui G, Chen X and Wu D: High concentrations of uric acid and angiotensin II act additively to produce endothelial injury. Mediators Inflamm 2020: 8378654, 2020.

21. Yang B, Li S, Zhu J, Huang J, Zhang A, Jia Z, Ding G and Zhang Y: miR‑214 protects against uric acid‑induced endothelial cell apoptosis. Front Med (Lausanne) 7: 411, 2020.

22. Durwald C, Mele L, Landon MB, Varner MW, Casey BM, Reddy UM, Wapner RJ, Rouse DJ, Tita ATN, Thorp JM Jr, et al: Fibroblast growth factor 21 and metabolic dysfunction in women with a prior glucose‑intolerant pregnancy. Am J Perinatol 38: 1380‑1385, 2020.

23. Lee SY, Burns SF, Ng KK, Stensel DJ, Zhong L, Tan FHY, Chia KL, Fan M, Yao MPC, Kuo I, et al: Fibroblast growth factor 21 mediates the associations between exercise, aging, and glucose regulation. Med Sci Sports Exerc 52: 370‑380, 2020.

24. Wu L, Qian L, Zhang L, Zhang J, Zhou J, Li Y, Hou X, Fang Q, Li H and Jia W: Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. J Am Heart Assoc 9: e015226, 2020.

25. Osman A, El‑Gamal H, Pasha M, Zeidan A, Korashy HM, Abdelsalam SS, Hasan M, Benemur T and Aouini A: Endoplasmic reticulum (ER) stress‑generated extracellular vesicles (microparticles) self‑perpetuate ER stress and mediate endothelial cell dysfunction independently of cell survival. Front Cardiovasc Med 7: 845, 2020.

26. Guo G, Guo R, Su Y, Fu J, Wang S, Kong Y, Wu C, Wang J, Tan C, Mo C and Zhao B: The PERK/eIF2alpha/ATF4/CHOP pathway plays a role in regulating monoracrine‑induced endoplasmic reticulum stress in rat liver. Res Vet Sci 130: 237‑239, 2020.

27. Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C, Chen G, Shen Y, Zhang H, Zheng J, et al: Fibroblast growth factor 21 protects the heart from angiotensin II‑induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Cardiovasc Med 7: 845, 2020.

28. Wu X, Wang Y, Hou L, Xiong Y and Zhao S: Fibroblast growth factor 21 (FGF21) promotes formation of aerobic myofibers via the FGB‑SIRT1‑AMPK‑PGC1alpha pathway. J Cell Physiol 232: 1893‑1906, 2017.

29. Li W, Cao T, Luo C, Cai J, Zhou X, Xiao X and Liu S: Crosstalk between ER stress, NLRP3 inflammasome, and inflammation. Appl Microbiol Biotechnol 104: 6129‑6140, 2020.

30. Zeng Z, Zheng Q, Chen J, Tan X, Li Q, Ding L, Zhang R and Lin X: FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome‑mediated vascular endothelial cells pyroptosis. Exp Cell Res 393: 11208, 2020.

This work is licensed under a Creative Commons Attribution‑NonCommercial‑NoDerivatives 4.0 International (CC BY‑NC‑ND 4.0) License.